the Difference of Follow-up Methods of Neonatal Jaundice

Launched by GUIZHOU PROVINCIAL PEOPLE'S HOSPITAL · Oct 4, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how different follow-up methods can help prevent severe jaundice in newborns. Jaundice is when a baby’s skin and eyes turn yellow due to high levels of bilirubin, a substance that can be harmful in large amounts. In this study, parents of babies with jaundice can choose between two follow-up methods: one that uses online tools and resources, and the traditional method where they visit a clinic. The researchers will collect information on how effective each method is in reducing severe jaundice and how easy they are for families to use.

To participate in the trial, babies need to be at least 28 weeks old and have some yellowing of the skin but not severely high levels of bilirubin. The baby should also be stable and ready for discharge from the hospital. Parents will need to agree to join the study and be able to understand and follow the instructions. Throughout the trial, families can expect to receive support and guidance on whichever follow-up method they choose, helping to ensure their baby stays healthy.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Gestational age ≥ 28 weeks, corrected gestational age ≤ 44 weeks;
• • 2. Presence of skin yellowing, percutaneous measurement of jaundice or serum bilirubin concentration less than the phototherapy warning value for the same gestational age and day age group;
• • 3. The vital signs are stable and meet the discharge requirements;
• • 4. Agree to participate in this project and sign an informed consent form;
• • 5. Parents have a certain understanding ability to cooperate in this study;
• Exclusion Criteria:
• • 1. Direct bilirubin ≥34mmol/L;
• • 2. Increased hepatic enzyme level more than twice of normal value;
• • 3. Those infants who have developed bilirubin encephalopathy or neurological damage due to other reasons before follow-up;
• • 4. Unable to continue follow-up due to other diseases.